Equine herpesvirus-1 (EHV-1) is a highly contagious alphaherpesvirus that primarily affects equids but has demonstrated the capacity to cross species barriers and cause severe neurological disease in New World camelids (llamas and alpacas).
Overview and Clinical Importance
Equine herpesvirus-1 (EHV-1) is a highly contagious alphaherpesvirus that primarily affects equids but has demonstrated the capacity to cross species barriers and cause severe neurological disease in New World camelids (llamas and alpacas). While cervids (deer, elk, moose) are not natural hosts for EHV-1, understanding the comparative susceptibility and differential diagnoses for neurological diseases in these species is essential for the NAVLE. This study guide covers the pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of EHV-1-associated meningoencephalitis, optic neuritis, and chorioretinitis in camelids, with relevant comparisons to cervid neurological diseases.
High-YieldEHV-1 is the ONLY herpesvirus known to cause clinical neurological disease in camelids. Unlike in horses where 80% or more are latently infected, camelids are considered aberrant or spillover hosts with potentially more severe disease outcomes including blindness and death.
| Feature |
Description |
| Classification |
Alphaherpesvirus; also called Equid alphaherpesvirus-1 |
| Genome |
Double-stranded DNA, approximately 150 kb |
| Key Strains |
D752 (neuropathogenic) and N752 (non-neuropathogenic) based on DNA polymerase gene polymorphism |
| Environmental Survival |
Up to 2-3 weeks on surfaces; inactivated by common disinfectants |
| Latency |
Establishes latency in trigeminal ganglia and lymphoid tissue; reactivates with stress |
Etiology and Virology
Virus Characteristics
Equine herpesvirus-1 (EHV-1) belongs to the family Herpesviridae, subfamily Alphaherpesvirinae. It is a double-stranded DNA virus with an enveloped virion structure. The virus is relatively stable in the environment but susceptible to common disinfectants, detergents, and desiccation.
Key Viral Features
NAVLE TipThe D752 strain is associated with 80-90% of neurological outbreaks, but remember that BOTH D752 and N752 strains can cause myeloencephalopathy (EHM). The mutation affects the DNA polymerase gene and results in higher viremia levels.
Host Range and Species Susceptibility
While EHV-1 primarily affects equids (horses, donkeys, mules, zebras), it has demonstrated the ability to infect non-equine species. The 1988 outbreak in New York documented the first major epizootic of EHV-1 in New World camelids, where blindness and encephalitis occurred in alpacas and llamas that had been housed near horses.
High-YieldCervids have their own species-specific herpesvirus (Cervid herpesvirus-1, CvHV-1) that causes respiratory disease, abortion, and rarely neurological signs. EHV-1 and CvHV-1 are antigenically distinct and do not cross-protect.
| Species |
Susceptibility to EHV-1 |
Clinical Manifestations |
| Equidae |
Primary natural host; 80% or more latently infected |
Respiratory disease, abortion, EHM, chorioretinopathy |
| Camelidae |
Aberrant/spillover host; severe disease when infected |
Encephalitis, blindness, chorioretinitis, death |
| Cervidae |
Not a natural host; cervid herpesvirus-1 (CvHV-1) is species-specific |
No documented natural EHV-1 infection; CWD and EEE are primary neurological concerns |
Pathogenesis
Mechanism of Neurological and Ocular Disease
The pathogenesis of EHV-1 neurological disease involves a complex cascade of events following initial respiratory infection:
- Primary Infection: Virus enters via the respiratory tract and replicates in epithelial cells of the nasopharynx and upper airways
- Lymphatic Spread: Virus spreads to regional lymph nodes and infects mononuclear cells (lymphocytes, monocytes)
- Cell-Associated Viremia: Infected leukocytes carry virus systemically while protected from neutralizing antibodies
- Endothelial Targeting: Virus transfers from infected PBMCs to vascular endothelium of target organs (CNS, eye, pregnant uterus)
- Vasculitis and Thrombosis: Endothelial infection triggers vasculitis, platelet activation, and thrombus formation
- Ischemic Injury: Thrombotic occlusion causes ischemic necrosis of neural tissue, leading to myeloencephalopathy and chorioretinopathy
Exam Focus: The key concept is that EHV-1 neurological disease is NOT caused by direct viral invasion of neurons. Instead, it is a VASCULAR disease caused by vasculitis and thrombosis in CNS blood vessels. This is why anticoagulants (heparin) have shown promise in treatment.
Tissue Tropism and Lesion Development
| Target Tissue |
Pathological Mechanism |
Clinical Result |
| Spinal Cord |
Vasculitis of small vessels leading to thrombosis, hemorrhage, and ischemic necrosis |
Ataxia, paresis, paralysis, urinary incontinence (myeloencephalopathy) |
| Brain |
Meningeal and parenchymal vasculitis with perivascular cuffing |
Depression, head pressing, seizures, cranial nerve deficits (encephalitis) |
| Choroid/Retina |
Choroidal vasculitis causing ischemic injury to retinal pigmented epithelium |
Multifocal 'shotgun' lesions, vision impairment, blindness (chorioretinopathy) |
| Optic Nerve |
Inflammation and vascular compromise of optic nerve head |
Acute vision loss, papilledema (optic neuritis) |
Clinical Signs
EHV-1 in Camelids
Clinical presentation in camelids often appears more severe than in horses, with a higher propensity for neurological and ocular involvement. The incubation period is typically 5-10 days post-exposure.
Neurological Signs
- Depression and apprehension (often first signs noted)
- Fever (39-40 degrees Celsius; 102-104 degrees Fahrenheit)
- Frothy salivation and oral discharge
- Head pressing and opisthotonus
- Ataxia, staggering gait, crossed limbs
- Hyperexcitability and ear fasciculations
- Blindness (often bilateral)
- Recumbency and inability to rise
- Progression to death often within 7-10 days of neurological onset
Ocular Signs
- Acute onset blindness (may be unilateral or bilateral)
- Dilated, unresponsive pupils
- Chorioretinitis visible on fundoscopic examination
- Multifocal depigmented 'shotgun' lesions on fundus
- Uveitis and severe ocular inflammation
High-YieldIn the landmark 1988 outbreak, four alpacas/llamas developed severe neurological disease with blindness. Virus was isolated from brain and eye tissues. Experimental intranasal inoculation of three llamas resulted in two developing severe neurological disease and one death, confirming EHV-1 pathogenicity in camelids.
| Disease |
Etiology |
Key Features |
Distinguishing Factor |
| EHV-1 |
Equine herpesvirus-1 |
Blindness, encephalitis, rapid progression |
Horse contact history; PCR positive |
| Meningeal Worm |
Parelaphostrongylus tenuis |
Asymmetric ataxia, paresis; common in eastern US |
White-tailed deer exposure; eosinophils in CSF |
| West Nile Virus |
Flavivirus (mosquito-borne) |
Asymmetric ataxia, sudden blindness, head tremors |
Summer/fall; 4-fold rise in serum titers |
| EEE |
Eastern Equine Encephalitis virus |
Acute CNS disease, seizures, sudden death |
Dead-end host; high mortality; mosquito season |
| Listeriosis |
Listeria monocytogenes |
Circling, head tilt, facial nerve paralysis |
Silage feeding; unilateral cranial nerve signs |
| Polioencephalomalacia |
Thiamine deficiency or sulfur toxicity |
Star-gazing, blindness, seizures |
Responds to thiamine; recent diet change |
| Rabies |
Lyssavirus |
Behavioral change, paralysis, death in 7-10 days |
Always fatal; zoonotic; FA testing on brain |
Differential Diagnosis
Neurological Diseases of Camelids
NAVLE TipWhen you see a camelid with BLINDNESS and ENCEPHALITIS, and there is history of horse contact, think EHV-1 first. Meningeal worm is the most common neurological disease overall in camelids in the eastern US, but it does NOT typically cause blindness.
"BLEW ME" = Blindness with encephalitis in camelids
B - Brain involvement (diffuse CNS signs)
L - Linked to horses (contact history)
E - Eyes affected (chorioretinopathy)
W - Widespread vasculitis pathology
M - Meningoencephalitis pattern
E - EHV-1 is the cause!
| Test |
Sample Type |
Interpretation |
| qPCR (Gold Standard) |
Nasal swab, buffy coat (EDTA blood), CSF, tissues |
Detects viral DNA; can differentiate D752/N752 strains |
| Virus Neutralization |
Serum (paired samples 2-3 weeks apart) |
4-fold rise in titer indicates active infection |
| CSF Analysis |
Cerebrospinal fluid via atlanto-occipital tap |
Xanthochromia, increased protein (100-500 mg/dL), normal to mildly elevated WBC |
| Virus Isolation |
Nasal swab, blood, CNS tissue (post-mortem) |
Definitive but time-consuming; may take 1-2 weeks |
| Histopathology |
Brain, spinal cord, eye (post-mortem) |
Vasculitis, thrombosis, perivascular cuffing, intranuclear inclusion bodies |
| IHC |
Fixed tissues |
Detects EHV-1 antigen in vascular endothelium |
Diagnosis
Diagnostic Approach
Definitive diagnosis of EHV-1 neurological disease requires a combination of clinical findings, epidemiological history, and laboratory confirmation. A presumptive diagnosis can be made based on clinical signs in an animal with known horse exposure.
High-YieldSubmit BOTH nasal swab AND blood in EDTA for PCR testing. Nasal shedding may precede neurological signs, while buffy coat PCR detects cell-associated viremia. CSF abnormalities may NOT be present early in disease; xanthochromia (yellow discoloration) indicates hemorrhage from vasculitis.
| Treatment |
Dosage/Protocol |
Rationale |
| Valacyclovir |
20-40 mg/kg PO q8h (dose extrapolated from equine use) |
Antiviral; reduces viral replication and viremia; most effective when started early |
| Flunixin Meglumine |
1.1 mg/kg IV or PO q12-24h |
NSAID; controls fever, reduces inflammation, may inhibit cell-to-cell viral spread |
| Heparin |
40-100 IU/kg SC q8-12h (unfractionated) or LMWH |
Anticoagulant; prevents thrombosis; may block viral entry into cells |
| DMSO |
0.5-1 g/kg IV as 10% solution (controversial) |
Anti-inflammatory; reduces CNS edema; efficacy unproven |
| IV Fluids |
Balanced crystalloids to maintain hydration |
Supportive care; maintain perfusion and hydration |
| Corticosteroids |
Dexamethasone 0.05-0.1 mg/kg IV (CONTROVERSIAL) |
May reduce inflammation but can enhance viral replication; use with caution |
Treatment
There is no specific cure for EHV-1 neurological disease. Treatment is primarily supportive with the goal of managing inflammation, preventing thrombosis, and providing nursing care.
Exam Focus: Heparin has shown promise in reducing EHM incidence in horses during outbreaks (3.2% vs 23.3% in one study). The mechanism involves BOTH anticoagulation AND blocking viral entry into endothelial cells. Low-molecular-weight heparin may be more effective than unfractionated heparin.
Prognosis
- Animals that remain ambulatory have a fair prognosis with supportive care
- Recumbent animals have a poor to grave prognosis
- Blindness from chorioretinopathy is often permanent
- Mortality rate of 30-50% in horses with EHM; may be higher in camelids
| Disease |
Etiology |
Clinical Signs |
Key Features |
| CWD |
Prion disease |
Wasting, behavioral changes, ataxia, death |
Always fatal; long incubation; USDA reportable |
| EHD/BTV |
Orbivirus (Culicoides-borne) |
Fever, hemorrhage, lameness, sudden death |
Summer/fall; midge-transmitted; may have neurological signs |
| Meningeal Worm |
P. tenuis (white-tailed deer = definitive host) |
Asymmetric ataxia, paresis in aberrant hosts |
WTD are asymptomatic carriers; camelids/moose get disease |
| Rabies |
Lyssavirus |
Behavioral change, paralysis, death |
Zoonotic; always fatal; wildlife reservoir |
Prevention and Control
Biosecurity Measures
Because camelids are spillover hosts for EHV-1, prevention focuses on minimizing contact with horses and implementing strict biosecurity:
- Separate housing: Do not house camelids in nose-to-nose contact with horses
- Dedicated equipment: Use separate feed/water buckets, halters, and grooming tools
- Personnel hygiene: Change clothing and footwear between equine and camelid areas
- Quarantine: Isolate new animals for 21 days minimum
- Monitoring: Take daily temperatures during high-risk periods
- Disinfection: Use effective disinfectants (phenolics, accelerated hydrogen peroxide, quaternary ammonium compounds)
Vaccination
- No vaccines are specifically licensed for EHV-1 in camelids
- Equine EHV vaccines are NOT proven effective in camelids
- If used off-label, ONLY killed vaccines should be considered
- Current equine vaccines do NOT prevent EHM in horses and are unlikely to do so in camelids
High-YieldThe AAEP and ACVIM state that NO currently available EHV vaccine reliably prevents neurological disease (EHM). Vaccination may reduce respiratory disease severity and viral shedding but does NOT prevent viremia or CNS infection.
Cervidae: Comparative Considerations
While cervids (deer, elk, moose) are NOT natural hosts for EHV-1, understanding their neurological diseases is important for differential diagnosis and comparative medicine. Cervids have their own species-specific herpesvirus (Cervid herpesvirus-1, CvHV-1) that causes different clinical syndromes.
Major Neurological Diseases of Cervids
NAVLE TipChronic Wasting Disease (CWD) is the most important NAVLE topic for cervid neurological disease. Remember: CWD is caused by PRIONS (not a virus), affects deer, elk, moose, and reindeer, has a long incubation (months to years), is ALWAYS FATAL, and requires post-mortem diagnosis with IHC or ELISA of lymphoid tissue.